carvedilol has been researched along with salmeterol xinafoate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, JG | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bond, RA; Corry, DB; Frazier, V; Kheradmand, F; Kim, C; Kim, JJ; Knight, JM; Luong, A; Mak, G; Mandal, PK; McDermott, C; McMurray, JS; Millien, VO; Milner, JD; Porter, P; Qian, Y; Roberts, L; Shaw, J; Song, LZ; You, R; Yuan, X; Zhang, Y | 1 |
| Bastiancich, C; De Backer, L; De Smedt, SC; Joris, F; Raemdonck, K; Van de Vyver, T | 1 |
| Bouvier, M; Gmeiner, P; Hübner, H; Kaindl, JM; Picard, LP; Schmidt, MF; Stanek, M; Weikert, D | 1 |
6 other study(ies) available for carvedilol and salmeterol xinafoate
| Article | Year |
|---|---|
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Cell Line; CHO Cells; Cricetinae; Dioxoles; Humans; Propanolamines; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Adrenergic, beta-3 | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Long-Acting Beta Agonists Enhance Allergic Airway Disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Anti-Asthmatic Agents; Arrestins; Aspergillosis, Allergic Bronchopulmonary; Aspergillus niger; Asthma; beta-Arrestins; Bronchoconstriction; Carbazoles; Carvedilol; Disease Models, Animal; Female; Formoterol Fumarate; Gene Expression; Humans; Lung; Mice; Mice, Knockout; Peptidomimetics; Propanolamines; Receptors, Adrenergic, beta-2; Salmeterol Xinafoate; STAT6 Transcription Factor | 2015 |
Repurposing cationic amphiphilic drugs as adjuvants to induce lysosomal siRNA escape in nanogel transfected cells.
Topics: Adjuvants, Pharmaceutic; Carvedilol; Cell Cycle Proteins; Cell Line, Tumor; Dextrans; Fluorescein-5-isothiocyanate; Gels; Green Fluorescent Proteins; Humans; Loratadine; Lysosomes; Nanoparticles; Nortriptyline; Oligonucleotides; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Small Interfering; Salmeterol Xinafoate; Transfection | 2018 |
Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; beta-Arrestins; Carvedilol; Catechols; Drug Design; GTP-Binding Proteins; Humans; Hydrogen Bonding; Indicators and Reagents; Isoproterenol; Ligands; Mice; Models, Molecular; Molecular Dynamics Simulation; Salmeterol Xinafoate | 2019 |